| ［1］ |
Fargnoli MC, Peris K, Frascione P, et al. Psoriasis, Kaposi′s sarcoma and Hodgkin′s disease in a patient with Down′s syndrome［J］. Dermatology, 2004,209（2）:158⁃159. doi: 10.1159/000079604.
|
| ［2］ |
Madani A, Almuhaideb Q. Adalimumab therapy in a patient with psoriasis, Down syndrome, and concomitant hepatitis B virus infection［J］. Biologics, 2021,15:375⁃378. doi: 10.2147/BTT.S317888.
|
| ［3］ |
Coimbra S, Santos⁃Silva A. Biomarkers of psoriasis severity and therapy monitoring［J］. World J Dermatol, 2014,3（2）:15⁃27. doi:10.5314/wjd.v3.i2.15.
|
| ［4］ |
Sismour B, DʼAcunto K. Down syndrome, severe psoriasis, and increased risk for cardiovascular events［J］. JAAPA, 2019,32（12）:31⁃33. doi: 10.1097/01.JAA.0000604860.71819.c1.
|
| ［5］ |
Ryan C, Vellody K, Belazarian L, et al. Dermatologic conditions in Down syndrome［J］. Pediatr Dermatol, 2021,38（Suppl 2）:49⁃57. doi: 10.1111/pde.14731.
|
| ［6］ |
Rork JF, McCormack L, Lal K, et al. Dermatologic conditions in Down syndrome: a single⁃center retrospective chart review［J］. Pediatr Dermatol, 2020,37（5）:811⁃816. doi: 10.1111/pde.14214.
|
| ［7］ |
Alcaide AJ, Barrera MV, Habicheyn S, et al. Safety of etanercept therapy in a patient with psoriasis, Down′s syndrome and concomitant hepatitis C virus infection［J］. J Eur Acad Dermatol Venereol, 2008,22（12）:1514⁃1516. doi: 10.1111/j.1468⁃3083. 2008.02693.x.
|
